FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62179
Company■ Unclear/unknown
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 12:00 UTC
LAST UPDATE2026-10-02 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Regeneron Phase 3 MASLD trial expands its metabolic pipeline, a long-term optionality signal.
Regeneron MASLD trial adds metabolic pipeline optionality
CATALYST TO WATCH
Trial enrollment and interim data
MAIN RISK
Trial may fail or face delays
FULL DISPATCH
Sponsor: Regeneron Pharmaceuticals; Status: Not Yet Recruiting; Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD; Interventions: ALN-CIDEB, Placebo; Enrollment: 1500 (estimated); First posted: 2026-10-02; NCT: NCT07854782
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
→CORRELATIONshares Healthcare
Your health insurance premiums may take a big jump in 2027 — here's why2026-10-02 16:26 UTC
Your health insurance premiums may take a big jump in 2027 — here's why2026-10-02 16:26 UTC
←CORRELATIONshares Healthcare
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 21:42 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 21:42 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.